ALGO +1.61% Amid Phase 2 B-SUPREME Study Updates

On JAN 22 2026, ALGO rose by 1.61% within 24 hours to reach $0.1196, despite a 9.05% decline over the past week. The asset has gained 8.24% over both the last 30 days and the last 12 months, reflecting a mixed performance amid ongoing developments in the biopharmaceutical sector.

Phase 2 B-SUPREME Study Progress on Track for 2026

Aligos Therapeutics, Inc. (NASDAQ: ALGS) has reported updates on its Phase 2 B-SUPREME clinical trial of pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection. As of January 2026, 144 subjects are enrolled globally, with enrollment milestones met for both planned interim analyses.

The first interim analysis is expected in the first half of 2026 and will assess data from approximately 36 HBeAg-negative participants who completed 12 weeks of treatment. A second interim analysis is planned for the second half of the year, examining data from 55 HBeAg-positive participants who have completed 24 weeks of treatment.

Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO of Aligos, highlighted the importance of these analyses in gaining directional insights into the study’s trajectory. Topline data from the full 48-week study is anticipated in 2027.

Leadership Transition and Strategic Hiring

Hardean Achneck, MD, resigned as Executive Vice President and Chief Medical Officer. The company has initiated a search for his successor, underscoring its ongoing focus on building a robust leadership team.

In a recent strategic move, Aligos appointed James Hassard as Executive Vice President and Chief Commercial Officer. Hassard brings extensive experience in commercial strategy, positioning the company to scale its operations as it advances its pipeline.

Clinical and Pipeline Highlights

Pevifoscorvir sodium is an oral small molecule capsid assembly modulator designed for chronic HBV infection. The compound has shown promising results in earlier Phase 1 studies, including sustained reductions in HBV markers and a favorable safety profile.

The B-SUPREME study is evaluating the drug’s safety and efficacy compared to tenofovir disoproxil fumarate, the current standard of care. This randomized, global trial is expected to enroll approximately 200 treatment-naïve adults with chronic HBV infection.

Analyst and Market Reactions

Following the recent updates, Aligos’ stock increased by 3.1% on January 22. The company’s progress has drawn attention from analysts, including UBS, which has initiated coverage with a Buy rating and a $20.00 price target. The firm cited the company’s undervalued market position and the blockbuster potential of its liver disease programs.

Conclusion

Aligos Therapeutics continues to advance its clinical development pipeline amid evolving leadership and strategic commercial planning. With two interim analyses scheduled in 2026 and topline data expected in 2027, the company remains on track to deliver key insights into its HBV therapy. These developments have contributed to ALGO’s 1.61% price rise on JAN 22 2026, despite broader volatility over the past week.